Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
CXL has been proven effective to treat patients with corneal ectasias.
Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.
The company is rolling out the Biovance 3L ocular tri-layer human amniotic membrane.
When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.
Corneal cross-linking (CXL) is improving all the time, although all protocols retain the basic requirements for oxygen, riboflavin and UV light. Recent developments mean that CXL at the slit lamp is feasible, which will improve access to the procedure.
According to UC Davis researchers, more needs to be done for the field to reflect ethnic and racial diversity across the country.
According to the university, the grant will support examining impact of pain and inflammation on eye’s surface and possible link to diseases.
According to the company, the multicenter US study enrolled more than 900 subjects with moderate-to-severe dry eye disease with topline data anticipated in the second quarter of 2023.
This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.
Medicare’s 2023 fee schedule includes cuts in reimbursement, which some groups say could lead to reduced access to care to patients who need it most.
An end-of-week review of what happened in ophthalmology from 29 October to 3 November 2022.
One clinician advises investigating prospective patients for history and evidence suggesting HSV keratitis, and monitoring for post-surgery epithelial defects.
Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.
Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.
Gentle eye drops, laser or minimally invasive surgery, advising patients on safe viewing of electronic devices, and addressing eyelid disorders can all help to minimise adverse effects.
The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.
Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.
Marjan Farid, MD, discussed the latest updates in femtosecond laser keratoplasty during a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago. She shared the highlights of that presentation here.
Complimentary registration is open for this unique meeting designed to prepare young ophthalmologists for success in early practice.
There literally are not enough hours in a day to allow physicians to comply with all the recommendations emanating from the various constituencies involved in issuing guidelines.
Ula V. Jurkunas, MD, discusses a presentation she gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of limbal stem cells to treat corneal blindness.
Methods using a combination of non-invasive thermal treatments and meibomian gland expression seem to be particularly effective.
